<DOC>
	<DOCNO>NCT01004991</DOCNO>
	<brief_summary>This phase I/II open label , multi-center study azacytidine combination standard RCHOP therapy patient DLBCL . Patients treat azacytidine escalating dos day 1-5 , follow standard dose rituximab plus CHOP chemotherapy day 8 , every 21 day . Patients treat total 6 cycle . The phase II portion evaluate efficacy combination establish MTD .</brief_summary>
	<brief_title>Phase I/II Trial R-CHOP + Azacytidine Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients must histologically confirm DLBCL characteristic immunophenotypic profile . Tumor tissue must confirm express CD20 antigen flow cytometry immunohistochemistry . Patients must least one site measurable disease , 1.5 cm diameter great . Patient previous treatment . Stage II ( appropriate abbreviate chemoimmunotherapy radiotherapy ) , III IV disease Able adhere study visit schedule protocol requirement . Patients must laboratory test result within range : Absolute neutrophil count &gt; = 1500/mm³ Platelet count &gt; = 75,000/mm³ Serum creatinine &lt; = 1.5X upper limit normal ( ULN ) Total bilirubin &lt; = 1.5X ULN . Higher level acceptable attribute active hemolysis ineffective erythropoiesis . AST ( SGOT ) ALT ( SGPT ) &lt; = 2 x ULN Disease free prior malignancy &gt; = 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . Women childbearing potential must negative serum pregnancy test prior azacitidine treatment . Women childbearing potential advise avoid become pregnant men advise father child receive treatment azacitidine . The effect azacytidine develop human fetus recommend therapeutic dose unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Age &gt; 18 year . Ability understand willingness sign write informed consent document . ECOG performance status 02 Patients must serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Patients must condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 28 day baseline . Concurrent use anticancer agent treatment . Known positive HIV infectious hepatitis B . Known central nervous system involvement lymphoma . Known suspected hypersensitivity azacitidine mannitol . Patients must advance malignant hepatic tumor . Pregnant lactate woman exclude study risk unborn fetus potential risk nurse infant unknown .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>